Randomized trials of gemtuzumab ozogamicin (GO).
| Trial . | Comparison . | Status . |
|---|---|---|
| MRC AML15 | Induction chemotherapy ± GO/consolidation ± GO in patients < 60 y | Induction completed n = 1113 |
| SWOG106 | Induction chemotherapy ± GO/maintenance GO vs nil in patients < 60 y | Consolidation ongoing n = 900+ Ongoing—result expected 2010 |
| ECOG E1900 | Randomized to receive or not GO prior to autologous stem cell transplantation | Ongoing |
| HOVON 43 | Randomized to receive GO as maintenance or not in older patients | Ongoing |
| GIMEMA-EORTC AML17 | Randomized to GO followed by chemotherapy induction vs chemotherapy alone, followed by 2 courses of consolidation ± GO in older fit patients | Ongoing—recruitment complete by end 2007 |
| GIMEMA AML19 | GO as monotherapy vs best supportive care in elderly unfit | Ongoing |
| MRC AML14/16 | Low-dose Ara-C vs low-dose Ara-C + GO in elderly unfit | Ongoing |
| MRC AML16 | Dauno/Ara-C vs Dauno/Clofarabine each ± GO in patients > 60 y who are fit for intensive chemotherapy | Ongoing |
| Trial . | Comparison . | Status . |
|---|---|---|
| MRC AML15 | Induction chemotherapy ± GO/consolidation ± GO in patients < 60 y | Induction completed n = 1113 |
| SWOG106 | Induction chemotherapy ± GO/maintenance GO vs nil in patients < 60 y | Consolidation ongoing n = 900+ Ongoing—result expected 2010 |
| ECOG E1900 | Randomized to receive or not GO prior to autologous stem cell transplantation | Ongoing |
| HOVON 43 | Randomized to receive GO as maintenance or not in older patients | Ongoing |
| GIMEMA-EORTC AML17 | Randomized to GO followed by chemotherapy induction vs chemotherapy alone, followed by 2 courses of consolidation ± GO in older fit patients | Ongoing—recruitment complete by end 2007 |
| GIMEMA AML19 | GO as monotherapy vs best supportive care in elderly unfit | Ongoing |
| MRC AML14/16 | Low-dose Ara-C vs low-dose Ara-C + GO in elderly unfit | Ongoing |
| MRC AML16 | Dauno/Ara-C vs Dauno/Clofarabine each ± GO in patients > 60 y who are fit for intensive chemotherapy | Ongoing |